Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.64 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.64 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.64 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | GNG2 | P59768 | 1/20 | 0.53 |
| ▸ | GNB1 | P62873 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30599806 | 1.00 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL31620935 | 0.88 | MAPT (0.71) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL5358935 | 0.88 | PRMT1 (0.80) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL5352933 | 0.88 | PRMT1 (0.62) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL7514702 | 0.84 | PRMT1 (0.60) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL20476791 | 0.83 | PRMT1 (0.59) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL13788695 | 0.83 | MAPT (0.57) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL499184 | 0.83 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO | |
| Dichlorofluorescein SCHEMBL29364373 | 0.83 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO | |
| SCHEMBL408340 | 0.83 | MAPT (0.64) | MAPTMEN1KMT2ATDP1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192788-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | L'OREAL (FR) | 2023-10-05 | — | — | WO | claimed |
| US-20230310285-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | L'OREAL (FR) | 2023-10-05 | — | — | US | claimed |
| US-12496344-B2 | Biophotonic materials and uses thereof | FLE INT S R L (IT) | 2025-12-16 | — | — | US | disclosed |
| US-11975221-B2 | Anti-microbial multilayer fabric media and method for making same | Shuai Danmeng (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240041739-A1 | BIOPHOTONIC COMPOSITIONS AND METHODS FOR PROVIDING BIOPHOTONIC TREATMENT | KLOX TECHNOLOGIES INC. (CA) | 2024-02-08 | — | — | US | disclosed |
| EP-4274443-A1 | ANTI-MICROBIAL MULTILAYER FABRIC MEDIA AND METHOD FOR MAKING SAME | Shuai, Danmeng (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230310285-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | L'OREAL (FR) | 2023-10-05 | — | — | US | disclosed |
| WO-2023192788-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | L'OREAL (FR) | 2023-10-05 | — | — | WO | disclosed |
| US-11723854-B2 | Biophotonic compositions and methods for providing biophotonic treatment | FLE INTERNATIONAL S.R.L. (IT) | 2023-08-15 | — | — | US | disclosed |
| US-20220387592-A1 | BIOPHOTONIC COMPOSITIONS AND METHODS FOR PROVIDING BIOPHOTONIC TREATMENT | FLE INTERNATIONAL S.R.L. (IT) | 2022-12-08 | — | — | US | disclosed |
| US-20220273798-A1 | INERT POLYMER-COATED BIOPHOTONIC SYSTEMS | FLE INTERNATIONAL S.R.L. (IT) | 2022-09-01 | — | — | US | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| EP-1229937-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT Inc. (CA) | 2002-08-14 | — | — | EP | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001085213-A2 | SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085212-A2 | DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| US-6284365-B1 | FOR CONTROLLING PHYSICAL PROPERTIES OF SURFACE AND INTERFACE OF SOLID ARTICLE SUCH AS WETTABILITY, ADHESIVE PROPERTY, SURFACE ENERGY, DISPERSABILITY, CHEMICAL RESISTANCE | FUJI XEROX CO., LTD. (JP) | 2001-09-04 | — | — | US | disclosed |
| WO-2001035996-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001035997-A2 | USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | MAPT 1710/4885MEN1 2343/4885KMT2A 2286/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | MAPT 1243/4885MEN1 2685/4885KMT2A 2520/4885 |
| US-20230310285-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | TYR, CYB5R3, POLR1C | MAPT 3307/4885MEN1 2132/4885KMT2A 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.